Canna~Fangled Abstracts

Medical Cannabis for Headache Pain: a Primer for Clinicians

By October 9, 2021October 11th, 2021No Comments

doi: 10.1007/s11916-021-00974-z.



Purpose of review: Public acceptance of Cannabis sativa L. (cannabis) as a therapeutic option grows despite lags in both research and clinician familiarity. Cannabis-whether as a medical, recreational, or illicit substance-is and has been commonly used by patients. With ongoing decriminalization efforts, decreased perception of harms, and increased use of cannabis in the treatment of symptoms and disease, it is critical for clinicians to understand the rationale for specific therapies and their medical and practical implications for patients. In view of the opioid crisis, overall patient dissatisfaction, and lack of adherence to current chronic pain and headache therapies, this review provides up-to-date knowledge on cannabis as a potential treatment option for headache pain.

Recent findings: Research into the use of cannabinoids for disease treatment have led to FDA-approved drugs for seizures, nausea, and vomiting caused by cancer chemotherapy; and for decreased appetite and weight loss in people with HIV/AIDS. For a wide variety of conditions and symptoms (including chronic pain), cannabis has gained increasing acceptance in society. The effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) in pain pathways have been significantly elucidated. An increasing number of retrospective studies have shown a decrease in pain scores after administration of cannabinoids, as well as long-term benefits such as reduced opiate use. Yet, there is no FDA-approved cannabis product for headache or other chronic pain disorders. More is being done to determine who is likely to benefit from cannabis as well as to understand the long-term effects and limitations of the treatment. Cannabis can refer to a number of products derived from the plant Cannabis sativa L. Relatively well-tolerated, these products come in different configurations, types, and delivery forms. Specific formulations of the plant have been shown to be an effective treatment modality for chronic pain, including headache. It is important for clinicians to know which product is being discussed as well as the harms, benefits, contraindications, interactions, and unknowns in order to provide the best counsel for patients.


Keywords: CBD, Cannabidiol, Cannabis sativa, Chronic migraine, Chronic pain, Dispensary, Endocannabinoid system, Legislation, Medical marijuana, Migraine treatment, Opioid crisis, Opioids, THC, Tetrahydrocannabinol


Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Dubois MY, Follett KA. Pain Medicine: The Case for an Independent Medical Specialty and Training Programs. Acad Med. 2014;89(6):863–8. . – DOI – PubMed
    1. Nahin RL. Estimates of Pain Prevalence and Severity in Adults: United States, 2012. J Pain. 2015;16(8):769–80. . – DOI – PubMed – PMC
    1. Elliott AM, Smith BH, Hannaford PC, Smith WC, Chambers WA. The course of chronic pain in the community: results of a 4-year follow-up study. Pain. 2002;99(1):299–307. . – DOI – PubMed
    1. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville: Substance Abuse and Mental Health Services Administration; 2013.
    1. Chambers J, Gleason RM, Kirsh KL, Twillman R, Webster L, Berner J, et al. An Online Survey of Patients’ Experiences Since the Rescheduling of Hydrocodone: The First 100 Days. Pain Med. 2016;17(9):1686–93. . – DOI – PubMed

Publication types

Leave a Reply

en English